We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

THERMO FISHER SCIENTIFIC

  Gold Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Sep 2021 - 25 Sep 2021

Blood Testing Distinguishes Benign Tumors from Precancerous Condition

By LabMedica International staff writers
Posted on 15 Sep 2021
Print article
Image: The Invitrogen Qubit 4 Fluorometer is designed to accurately measure DNA, RNA, and protein quantity (Photo courtesy of Thermo Fisher Scientific)
Image: The Invitrogen Qubit 4 Fluorometer is designed to accurately measure DNA, RNA, and protein quantity (Photo courtesy of Thermo Fisher Scientific)
The leading cause of mortality for patients with the neurofibromatosis type 1 (NF1) cancer predisposition syndrome is the development of malignant peripheral nerve sheath tumor (MPNST), an aggressive soft tissue sarcoma. In the setting of NF1, this cancer type frequently arises from within its common and benign precursor, plexiform neurofibroma (PN).

Despite the high incidence and mortality of MPNST in the NF1 population, screening for malignant transformation and monitoring of MPNST is challenging. Clinical examination has poor sensitivity and may only signify MPNST when a PN lesion is showing sudden growth or causing severe pain. Serial PN biopsies are impractical as 9% to 21% of NF1 patients will have multiple PN, with varying levels of malignant potential requiring surveillance.

Specialized Oncologists at Washington University School of Medicine (St. Louis, MO, USA) and their colleagues assessed cell-free DNA (cfDNA) in blood plasma samples from 16 unaffected volunteer individuals and 37 individuals with NF1 — including samples from 23 PN patients and 46 samples from 14 individuals with MPNST.

The team extracted cell-free DNA (cfDNA) was from plasma using the QIAamp Circulating Nucleic Acid kit (Qiagen, Hilden, Germany). Extracted DNA concentration was measured using the Qubit dsDNA High-Sensitivity assay (Thermo Fisher Scientific, Waltham, MA, USA), and cfDNA concentration and quality were assessed using a Bioanalyzer or Tapestation (Agilent Technologies, Santa Clara, CA, USA). Constructed libraries were balanced, pooled, and sequenced using 150 bp paired-end reads on a NovaSeq or HiSeq 4000 (Illumina, San Diego, CA, USA).

The investigators reported that based on cfDNA fragment sizes, copy number profiles, and genomic instability patterns, they developed a classifier that could discriminate between individuals with or without the tumor conditions while distinguishing the malignant and benign forms of disease with 86% accuracy (75% sensitivity and 91% specificity) in untreated individuals. In samples collected over time, the team reported, the cfDNA-based tool correctly classified 89% of the MPNST and PN cases, with 83% sensitivity and a specificity of around 91%. When the investigators quantified ctDNA in serial MPNST samples for their proof-of-concept analyses, they found that the approach may help in tracking treatment response and detecting relapse-related minimal residual disease after treatment at time points where MRD did not show up by radiographic imaging.

The scientists noted that plasma cfDNA from MPNST and PN patients harbored focal copy number loss of NF1 not found in healthy donors and that MPNST patient cfDNA also had significantly greater tumor genomic instability compared to PN, with copy number alterations in key genomic loci previously observed in MPNST tissue, which enabled sensitive and specific liquid biopsy discrimination of MPNST from PN.

The authors concluded that tumor fraction levels derived from cfDNA fragment size and copy number alteration analysis of plasma cfDNA using ultra-low-pass whole genome sequencing (ULP-WGS) significantly correlated with MPNST tumor burden, accurately distinguished MPNST from its benign PN precursor, and dynamically correlated with treatment response. In the future, their findings could form the basis for improved early cancer detection and monitoring in high-risk cancer-predisposed populations. The study was published on August 31, 2021 in the journal PLOS Medicine.

Related Links:
Washington University School of Medicine
Qiagen
Thermo Fisher Scientific
Agilent Technologies
Illumina


Gold Supplier
SARS-CoV-2 IGRA
SARS-CoV-2 IGRA
New
Clinical Chemistry Analyzer
Mispa CXL Pro
New
Silver Supplier
COVID-19 IgG-IgM Rapid Test
COVID-19 IgG-IgM Rapid Test
New
Gold Supplier
SARS-CoV-2/Flu A/B & RSV Test
RespiBio Panel 3 (RBRP3)

Print article

Channels

Pathology

view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more

Industry

view channel
Illustration

Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028

The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.